Pharma: A second wave of generics opportunity - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharma: A second wave of generics opportunity

Jul 2, 2010

Generic companies thrive when a large number of drugs lose patents. This largely holds true in the US generics market. After all, it is the biggest pharma market in the world. At the same time, because of the big opportunity there, many generic companies have made a beeline for the US. And the result -competition in this space has intensified. And prices have crashed. The only way to survive in this market then is to keep up the flow of product launches. And also identify products that have limited competition. The years 2006 and 2007 were particularly good for the global generics industry. This is when a large number of blockbuster drugs went off patent. After a lull, another generics opportunity now beckons especially for Indian pharma companies.

Between the years 2011 and 2013, a large number of drugs are expected to lose patents. These drugs represent US$ 80 bn in innovator sales. Thus, even after factoring in for competition and price erosion, the opportunity available is still better than what would have been otherwise.

Making the most of it

So how are Indian pharma companies geared to capitalise on this opportunity? The crux is 'products with limited competition'.

In this regard, Dr. Reddy's, Ranbaxy, Sun Pharma, Lupin, and Glenmark have some opportunities lined up. The biggest, however, seems to lie with Dr. Reddy's and Ranbaxy.

  • Dr. Reddy's: The company has made a conscious effort of focusing on niche products so that revenue and profit potential is higher. The company has several such opportunities lined up over the next three years. These are products with exclusivity periods. Products which are difficult to manufacture. Products for which it has settled legal suits with innovator companies among others. Little wonder then that the domestic pharma major has touted the US market to be a major growth driver going forward. The company has envisaged generating sales to the tune of US$ 3 bn by 2013. And the US is expected to be a big part of it. The major challenge then to Dr. Reddy's in this market will be delay in receiving approvals for all these products.

  • Ranbaxy: The company had outlined a strategy of launching one product with the exclusivity window every year. And it was also able to strike deals in this regard. For instance, GSK Plc's 'Imitrex' was an opportunity in 2008. Then there was 'Valtrex' in 2009. 'Flomax' in 2010. And the biggest of them all 'Lipitor' in 2011. Not just that there is another opportunity in the form of 'Nexium'. The latter is the second largest drug in the world. The biggest problem for Ranbaxy is its ongoing troubles with the US FDA. And so even with an ompressive product line up, the launch of some them is uncertain. Take 'Imitrex' for example. The company lost out on the opportunity to capitalise on this drug as the approval from the US FDA got significantly delayed. The silver lining in the cloud is that it was able to launch 'Valtrex' on time. And thus amass substantial revenues from the same. Now 'Lipitor' beckons next year. Even though one can reasonably assume that Ranbaxy will do all that it can to make this launch happen, its fate will finally be decided by the US regulator.
Going forward…

It is becoming increasingly clear that Indian pharma companies will have to do something extra special. This is more so if they want to sustain their revenues and profits in the highly competitive US generics market. No longer is it a simple case of competing in the market only on the basis of price.


Equitymaster requests your view! Post a comment on "Pharma: A second wave of generics opportunity". Click here!

1 Responses to "Pharma: A second wave of generics opportunity"

K P BHAT

Jul 15, 2010

How about 1,,. PIRAMAL HEALTHCARE /2. ZYDUS WELLNESS
3.TORENT PHARM?

Like 
  
Equitymaster requests your view! Post a comment on "Pharma: A second wave of generics opportunity". Click here!

More Views on News

DIVIS LABORATORIES at All Time High; BSE HEALTHCARE Index Down 0.2% (Market Updates)

Jan 28, 2020 | Updated on Jan 28, 2020

DIVIS LABORATORIES share price has hit an all time high at Rs 1,947 (up 1.5%). The BSE HEALTHCARE Index is down by 0.2%. Among the top gainers in the BSE HEALTHCARE Index today are DIVIS LABORATORIES (up 1.5%) and DR. REDDYS LAB (up 0.1%). The top losers include STRIDES PHARMA SCIENCE (down 0.1%) and CADILA HEALTHCARE (down 0.1%).

ASTRAZENECA PHARMA Surges by 5%; BSE HEALTHCARE Index Up 0.6% (Market Updates)

Jan 28, 2020 | Updated on Jan 28, 2020

ASTRAZENECA PHARMA share price has surged by 5% and its current market price is Rs 2,692. The BSE HEALTHCARE is up by 0.6%. The top gainers in the BSE HEALTHCARE Index are ASTRAZENECA PHARMA (up 5.4%) and SUN PHARMA ADV. RES. (up 5.1%). The top losers are BLISS GVS PHARMA (down 0.1%) and JUBILANT LIFE SCIENCES (down 0.1%).

TORRENT PHARMA Plunges by 5%; BSE HEALTHCARE Index Up 0.4% (Market Updates)

Jan 28, 2020 | Updated on Jan 28, 2020

TORRENT PHARMA share price has plunged by 5% and its current market price is Rs 2,022. The BSE HEALTHCARE is up by 0.4%. The top gainers in the BSE HEALTHCARE Index are SUN PHARMA ADV. RES. (up 5.5%) and SUVEN LIFESCIENCES (up 4.8%). The top losers is TORRENT PHARMA (down 5.1%).

WOCKHARDT Surges by 6%; BSE HEALTHCARE Index Down 0.1% (Market Updates)

Jan 28, 2020 | Updated on Jan 28, 2020

WOCKHARDT share price has surged by 6% and its current market price is Rs 374. The BSE HEALTHCARE is down by 0.1%. The top gainers in the BSE HEALTHCARE Index is WOCKHARDT (up 5.5%). The top losers are J.B.CHEMICALS and DIVIS LABORATORIES .

SHILPA MEDICARE Surges by 5%; BSE HEALTHCARE Index Down 0.1% (Market Updates)

Jan 28, 2020 | Updated on Jan 28, 2020

SHILPA MEDICARE share price has surged by 5% and its current market price is Rs 284. The BSE HEALTHCARE is down by 0.1%. The top gainers in the BSE HEALTHCARE Index is SHILPA MEDICARE (up 5.3%). The top losers are J.B.CHEMICALS and AJANTA PHARMA .

More Views on News

Most Popular

How to Buy the Best Safe Stocks in 2020 (The 5 Minute Wrapup)

Jan 17, 2020

Don't fall for the safe stocks narrative going around in the stock market these days.

Guess Which Stocks Are Rising at Double the Speed of Sensex (Profit Hunter)

Jan 15, 2020

These stocks can move twice as fast as the Sensex - to take advantage of their money multiplying power get in now as the rally is still just taking shape.. read more to not miss out.

For 1,000%+ Gains, Follow the 8-Year Cycle in the Stock Market (Fast Profits Daily)

Jan 17, 2020

This is how the biggest trading profits are made.

What the Infosys Results Tell Us About the Next Infosys (The 5 Minute Wrapup)

Jan 15, 2020

If you're interested in the next Infosys, I'll tell you where to look.

The Best Asset Class to Invest in 2020 (Fast Profits Daily)

Jan 24, 2020

Why I'm most bullish on this asset class above all else in 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Jan 28, 2020 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS